Accord BioPharma Logo
Scroll To Top Arrow

The promise: biosimilars are less expensive
and have more access benefits than the originator

Biosimilars represent the potential to increase access to vital treatments for patients and enhance the sustainability of the U.S. healthcare system through cost savings.

While they are highly similar to biologics, biosimilars are less expensive than their originator biologics (discounts vary by market and product), offering the potential to reduce prescription drug costs while providing patients a comparable level of safety and efficacy.1

As of 2023, more than 40 biosimilars have received regulatory approval in the U.S.—and counting.2 These helped create an estimated $13.3 billion in savings for the healthcare system since 2015.3 And biosimilars have proven resilient, with a steadily increasing market share.4

Read more

The biosimilars that have entered the market have launched with initial list prices anywhere from 15% to 35% lower than their biologic competitors.5 And a recent study from the RAND Corporation has estimated that biosimilar drugs will produce savings to the U.S. healthcare system of around $38.4 billion from 2021 to 2025, representing 5.9% of total U.S. spending on biologics.

Additionally, a 2023 study from IQVIA on biosimilars in the U.S. found that the market share maintained by originators after biosimilar competition is introduced is correlated with the relative reduction in the price of originator biologic compared to the biosimilar. In other words, biologic drugs generally lose less market share when they have reduced prices to similar levels as their biosimilar competitors.1

This data could mean that as more and more biosimilars are introduced to the U.S. market, biologics manufacturers will be more inclined to lower their average sales prices to maintain their volume, potentially leading to overall lower cost of these drugs, and increasing access to medicines in the US healthcare system.1

Collapse

Learn more about the key considerations for biosimilars with each of the following groups.

Patients

Learn more

Prescribers

Learn more

Payers

Learn more

Specialty Pharmacies

Learn more

To learn more about the promise of biosimilars, the impact they can create, and our work in this space, visit the following pages:

Going Beyond
Biosimilars

Understanding
Biosimilars

Our Commitment
to Biosimilars

1. Biosimilars in the United States 2023-2027. IQVIA. https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2023-2027. Published January 31, 2023.
2. Center for Drug Evaluation and Research. Biosimilar Drug Information. U.S. Food and Drug Administration. May 25, 2023. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information.
3. The U.S. Generic & Biosimilar Medicines Savings Report. Association for Accessible Medicines. September 2022. https://accessiblemeds.org/sites/default/files/2022-09/AAM-2022-Generic-Biosimilar-Medicines-Savings-Report.pdf.
4. U.S. biosimilars market size, growth, share: Forecast report, 2029. Fortune Business Insights. https://www.fortunebusinessinsights.com/industry-reports/u-s-biosimilars-market-100990. Published May 2022.
5. Decreasing drug costs through generics and Biosimilars. National Conference of State Legislatures. https://www.ncsl.org/health/decreasing-drug-costs-through-generics-and-biosimilars. Published January 21, 2022.

IMPORTANT SAFETY INFORMATION

Do not use CAMCEVI® in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of CAMCEVI as anaphylactic reactions to these drugs have been reported in the medical literature.

CAMCEVI, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment which can cause transient worsening of symptoms. As with other GnRH agonists, cases of ureteral obstruction and spinal cord compression, have been observed, which may contribute to paralysis with or without fatal complications.

Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Blood glucose levels should be monitored and managed according to current clinical practice.

Increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in association with the use of GnRH agonists. The risk appears low based on the reported odds ratios, and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients should be monitored for cardiovascular disease and be managed according to current clinical practice.

Androgen deprivation therapy may prolong the QT/QTc interval. Consider periodic monitoring of electrocardiograms and electrolytes.

Convulsions have been reported in patients receiving GnRH agonists, like CAMCEVI. Patients experiencing convulsions should be managed according to the current clinical practice.

Monitor serum levels of testosterone following injection of CAMCEVI.

Based on findings in animal studies and mechanism of action, CAMCEVI may cause fetal harm when administered to pregnant women.

The most common (≥10%) adverse reactions during a median follow-up of 336 days were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremity.

INDICATION

CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer.

Click here for full Prescribing Information.

Contact Us:
Discover:

©2024 Accord BioPharma, Inc. All rights reserved WS-ABI-2200001